Skip to main content

Drug Interaction Report

1 potential interaction and/or warning found for the following 2 drugs:

Add another drug
Filter by interaction and/or warning

Interactions between your drugs

Moderate

torsemide vemurafenib

Applies to: torsemide, vemurafenib

MONITOR: Coadministration with vemurafenib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C8. The proposed mechanism, based on in vitro data, is decreased clearance due to vemurafenib-mediated inhibition of CYP450 2C8.

MANAGEMENT: Caution is advised if vemurafenib is used concomitantly with drugs that are substrates of CYP450 2C8, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever vemurafenib is added to or withdrawn from therapy with these drugs. Since vemurafenib has a long half-life, a wash-out period of 8 days following the discontinuation of vemurafenib has been suggested to avoid an interaction with subsequent therapy. Patients should be monitored for the development of adverse effects.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."

Drug and food interactions

No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer